NCT04482283View on ClinicalTrials.gov

HF Prevalence and Evolution of HF in DM II Patients at High Risk

CompletedOBSERVATIONAL
Enrollment

244

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

November 21, 2024

Study Completion Date

November 21, 2024

Conditions
RELATED REGISTRY SEARCH
Trial Locations (10)

10676

Research Site, Athens

11526

Research Site, Athens

11527

Research Site, Athens

12462

Research Site, Athens

26504

Research Site, Pátrai

41110

Research Site, Larissa

54636

Research Site, Thessaloniki

54642

Research Site, Thessaloniki

68100

Research Site, Alexandroupoli

71500

Research Site, Heraklion

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT04482283 - HF Prevalence and Evolution of HF in DM II Patients at High Risk | Biotech Hunter | Biotech Hunter